Revance Theraputics (RVNC) Pipeline is Underappreciated - Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Revance Releases Fourth Quarter and Full Year 2015 Results
March 2, 2016 4:05 PM EST- Announces 2016 Outlook --Â On Track to Achieve Multiple Clinical Development Milestones in 2016 -
NEWARK, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today results for the fourth quarter and full year ended December 31, 2015 and provided its 2016 financial outlook.
Recent Highlights and Upcoming Milestones
Clinical Development - DaxibotulinumtoxinA Topical Gel (RT001) Continued active enrollment in REALISE 1, a Phase 3 trial for... More